Prognosis
J&J Ebola Shot Languishes, Making Merck Vaccine Only Option
- With Merck vaccine in use, officials want to avoid confusion
- No ‘crisis’ in supplies of Merck’s vaccine, June report says
This article is for subscribers only.
Johnson & Johnson’s experimental Ebola vaccine sits idle in a Dutch warehouse, ready to help counter the international crisis erupting in Africa -- if authorities decide to use it.
The Ebola epidemic that began a year ago has already killed more than 1,700 people and was declared a global public health emergency on Wednesday. World Health Organization officials have said that they have about 245,000 doses of an experimental vaccine from Merck & Co. that’s already in use, and that there’s a need for additional options.